EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance

Alessandro D Genazzani, Andrea R Genazzani

European Endocrinology · 2023 · 19 (1) · 71

DOI: 10.17925/ee.2023.19.1.71 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Endocrinology, 2023. Verfasst von Alessandro D Genazzani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gynaecological Endocrinology Center, Department of Obstetrics and Gynaecology, University of Modena and Reggio Emilia, Modena, Italy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This article is published under the Creative Commons Attribution Non-commercial License..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is a very frequent disease that affects reproductive ability and menstrual regularity. Other than the criteria established at the Rotterdam consensus, in these last few years a new issue, insulin resistance, has been found frequently, and at a very high grade, in patients with PCOS. Insulin resistance occurs for several factors, such as overweight and obesity, but it is now clear that it occurs in patients with PCOS with normal weight, thus supporting the hypothesis that insulin resistance is independent of body weight. Evidence shows that a complex pathophysiological situation occurs that impairs post-receptor insulin signalling, especially in patients with PCOS and familial diabetes. In addition, patients with PCOS have a high incidence of non-alcoholic fatty liver disease related to the hyperinsulinaemia. This narrative review focuses on the recent new insights about insulin resistance in patients with PCOS, to better understand the metabolic impairment accounting for most of the clinical signs/symptoms of PCOS.

Schlagwörter

Stichwörter der Autor:innen

Familial diabeteshyperinsulinemiainositolsinsulin resistancelipoic acidnon-alcoholic fatty liver diseasepolycystic ovary syndrome

Autor:innen und Institutionen

  • Gynaecological Endocrinology Center, Department of Obstetrics and Gynaecology, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Obstetrics and Gynaecology, University of Pisa, Pisa, Italy.

Förderung

  • This article is published under the Creative Commons Attribution Non-commercial License.

Zitieren

APA

Genazzani, A. D., & Genazzani, A. R. (2023). Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance. European Endocrinology, 19(1), 71. https://doi.org/10.17925/ee.2023.19.1.71

Vancouver

Genazzani AD, Genazzani AR. Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance. European Endocrinology. 2023;19(1):71. doi:10.17925/ee.2023.19.1.71

BibTeX
@article{Genazzani2023,
  author = {Genazzani, Alessandro D and Genazzani, Andrea R},
  title = {Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance},
  journal = {European Endocrinology},
  year = {2023},
  volume = {19},
  number = {1},
  pages = {71},
  doi = {10.17925/ee.2023.19.1.71}
}
Kostenlos starten →